Gastrointestinal Bleeding Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Endoscopic Hemostatic Devices (Thermal Devices, Mechanical Devices), Closure Devices, Others), By GI Tract Division (Upper GI Tract, Lower GI Tract), By End Users (Hospital/Clinics, Ambulatory Surgical Centres, Others), By Region, and By Competition, 2020-2030F

Market Overview

The Global Gastrointestinal Bleeding Treatment Market, valued at USD 562.44 Million in 2024, is projected to experience a CAGR of 5.88% to reach USD 792.34 Million by 2030. The Global Gastrointestinal Bleeding Treatment Market focuses on medical interventions designed to halt or manage blood loss originating within the gastrointestinal tract, encompassing the esophagus, stomach, small intestine, large intestine, and rectum, alongside addressing underlying causes and preventing complications. Key drivers supporting market expansion include the rising global incidence of gastrointestinal disorders such as peptic ulcers and colorectal cancer, coupled with the increasing adoption of minimally invasive endoscopic procedures offering improved patient outcomes.

According to the World Health Organization, the number of individuals aged 60 and above globally was expected to reach 1.1 billion in 2023, a demographic shift significantly contributing to heightened susceptibility to gastrointestinal bleeding. A notable impediment to market growth, however, remains the substantial cost associated with advanced diagnostic and therapeutic devices and procedures, which can limit accessibility in various healthcare systems.

Key Market Drivers

The increasing prevalence of gastrointestinal disorders significantly drives the Global Gastrointestinal Bleeding Treatment Market. Conditions such as peptic ulcers, gastritis, and colorectal cancer inherently carry a risk of bleeding, necessitating medical intervention. As the global burden of these diseases grows, the demand for effective diagnostic and therapeutic solutions for gastrointestinal bleeding escalates. For instance, according to the World Cancer Research Fund, there were 1,926,425 new cases of colorectal cancer globally in 2022, a disease frequently associated with gastrointestinal bleeding events requiring treatment. This rising incidence translates directly into a greater need for screening, early detection, and subsequent management of bleeding episodes across diverse patient demographics, thereby expanding the market for related treatments.

Concurrently, advancements in endoscopic and therapeutic technologies represent a pivotal growth factor. Continuous innovation in devices and techniques has enhanced the precision and efficacy of treating gastrointestinal bleeding, offering improved patient outcomes and reduced recovery times. Breakthroughs include more sophisticated imaging capabilities, miniaturized instruments, and novel hemostatic agents. According to *Gastrointestinal Endoscopy*, in January 2024, a multicenter clinical trial demonstrated that novel hemostatic powder reduced the 30-day risk of recurrent bleeding to 5.2% compared with 28.1% with standard endoscopic therapy across all gastrointestinal tumor locations. Such technological progress not only makes procedures safer and more accessible but also expands the range of treatable conditions, fostering increased adoption of these advanced interventions. This dynamic landscape of innovation is further supported by substantial industry activity; for example, according to *Towards Healthcare*, in August 2025, Boston Scientific Corporation, a leader in endoscopy devices, reported full-year 2024 revenue of $16.747 billion, an increase of 17.6% from the previous year.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with advanced diagnostic and therapeutic devices and procedures presents a significant challenging factor within the Global Gastrointestinal Bleeding Treatment Market. This financial impediment directly restrains market expansion by limiting the accessibility and widespread adoption of innovative, highly effective interventions, particularly in healthcare systems with constrained budgets and in developing nations. The high initial capital expenditure required for sophisticated endoscopes, specialized hemostatic instruments, and associated processing units often exceeds the financial capacity of numerous healthcare providers, hindering their ability to invest in these critical technologies.

This economic hurdle directly hampers market growth as hospitals and clinics face increased pressure to manage operational expenditures. According to AdvaMed, in February 2025, a survey indicated that 80% of healthcare supply chain professionals anticipated increased import expenses would raise costs by at least 15% for hospitals and health systems in the coming months. Such significant cost increases translate into delayed procurement cycles and reduced deployment of advanced GI bleeding treatment devices. Consequently, fewer patients can access optimal care, leading to suboptimal treatment outcomes and slower market penetration for cutting-edge solutions, thereby directly impeding the overall growth trajectory of the Global Gastrointestinal Bleeding Treatment Market.

Key Market Trends

The expansion of telehealth and remote monitoring in gastrointestinal bleeding management represents a significant evolution in healthcare delivery. This trend moves beyond traditional in-person visits to offer continuous patient oversight and enhanced post-discharge care. Telehealth platforms facilitate virtual consultations and enable remote patient monitoring through digital health tools, which supports timely interventions and improves patient engagement by providing convenience and accessibility, especially for individuals in remote areas or those facing mobility challenges. According to *Gastroenterology & Endoscopy News*, in March 2025, a pilot study indicated that an on-demand telehealth program successfully redirected 90% of gastrointestinal-related emergency department visits, highlighting its potential to optimize resource allocation and streamline patient pathways. This shift is increasing the demand for integrated digital solutions capable of continuous data collection and analysis, allowing providers to manage GIB more proactively.

The growing adoption of artificial intelligence in gastrointestinal bleeding diagnostics is fundamentally transforming the accuracy and speed of identifying bleeding sources. AI algorithms, particularly within endoscopic imaging and electronic health record analysis, are able to detect subtle anomalies that might be missed by human observation, thereby reducing diagnostic errors and facilitating earlier intervention. This technology augments the diagnostic capabilities of endoscopists by offering real-time analysis during procedures and can also predict recurrence risk from patient data. For instance, according to the *Yale School of Medicine*, in September 2024, a research team developed a large language model pipeline that accurately identified recurrent gastrointestinal bleeding in electronic health records 97% of the time, demonstrating a notable advancement over conventional methods. The increasing integration of AI in this field promotes the development of more sophisticated diagnostic tools and software, leading to improved patient outcomes and more efficient clinical workflows in GIB management.

Segmental Insights

The Upper GI Tract segment is experiencing rapid growth in the Global Gastrointestinal Bleeding Treatment Market due to several converging factors. A significant driver is the high prevalence of upper gastrointestinal bleeding conditions, including peptic ulcers, gastritis, and esophagitis, which necessitate effective treatment interventions. Additionally, the expanding geriatric population, inherently more susceptible to gastrointestinal bleeding and increased usage of non-steroidal anti-inflammatory drugs, contributes substantially to this growth. Furthermore, continuous advancements in endoscopic hemostasis applications and devices, coupled with a growing preference for minimally invasive procedures, enhance treatment efficacy and adoption within this segment. This combination of prevalent conditions, demographic shifts, and technological innovation underpins the segment's accelerated expansion.

Regional Insights

North America dominates the global gastrointestinal bleeding treatment market, primarily driven by its advanced and well-established healthcare infrastructure and significant healthcare expenditure. The region exhibits a high prevalence of gastrointestinal disorders, alongside a strong adoption of technologically advanced diagnostic and therapeutic interventions, including minimally invasive procedures. Furthermore, the robust presence of key medical device companies in North America fosters continuous innovation and product development, often supported by regulatory approvals from bodies such as the U. S. Food and Drug Administration. Favorable reimbursement policies and a high level of physician expertise further solidify the region's leading market position by enhancing access to effective treatments and promoting early detection.

Recent Developments

• In April 2025, Xgenera, a British technology company, engaged in breakthrough research in collaboration with the University of Southampton, receiving a £2.4 million government award to advance an AI-driven blood test named miONCO-Dx. This innovation aims to provide earlier, faster, and more affordable detection of bowel cancer, significantly reducing the reliance on invasive procedures like colonoscopies. Early diagnosis of bowel cancer is vital for improving patient outcomes and can preempt severe conditions, including gastrointestinal bleeding, by enabling timely and effective treatment. This research marks a substantial step forward in diagnostic capabilities within the gastrointestinal health market.

• In December 2024, PENTAX Medical, a division of HOYA Group, received US FDA 510(k) clearance for new models within its i20c Video Endoscope Series. These additions include the PENTAX Medical Video Colonoscope EC34-i20cL and the PENTAX Medical Video Upper GI Scope EG27‑i20c. Designed to integrate with the PENTAX Medical INSPIRA™ Video Processor EPK-i8020c, these endoscopes enhance detection, diagnosis, and therapeutic interventions for healthcare professionals. The new models offer advanced imaging capabilities, improved maneuverability through adjustable stiffness, and superior ergonomics, aiming to optimize clinical workflows and enhance the quality of procedures in the gastrointestinal tract, supporting the treatment of bleeding events.

• In December 2024, a significant company collaboration emerged in the endoscopy sector, as medtech company Insign Medical Technology partnered with artificial intelligence firm AAEON. This collaboration is focused on developing an AI-assisted endoscopy system known as EndoDASS. The new system integrates AAEON's BOXER-8641AI Fanless Embedded AI system with Insign’s specialized software. This partnership aims to leverage AI to enhance endoscopic procedures, offering potential advancements in the detection, diagnosis, and treatment of gastrointestinal conditions, including those that may lead to bleeding, by providing more precise and efficient visualization during examinations.

• In September 2024, Olympus Latin America introduced its advanced EVIS X1™ endoscopy system in Brazil, marking a significant product launch for the global gastrointestinal bleeding treatment market. This new system incorporates several visualization technologies, including Red Dichromatic Imaging (RDI™), which is specifically engineered to enhance the visibility of deep blood vessels and bleeding points during endoscopic procedures. The system also features an ergonomic design for improved handling. This launch expands the availability of sophisticated diagnostic and therapeutic tools, crucial for the precise identification and management of various gastrointestinal conditions, including sources of bleeding.

Key Market Players

• Boston Scientific Corporation
• Olympus Corporation
• CONMED Corporation
• Ovesco Endoscopy AG
• Erbe Elektromedizin GmbH
• Steris Plc
• US Medical Innovations, LLC
• Pfizer Inc.

Report Scope:

In this report, the Global Gastrointestinal Bleeding Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gastrointestinal Bleeding Treatment Market, By Product:

o   Closure Devices

o   Endoscopic Hemostatic Devices

o   Others

• Gastrointestinal Bleeding Treatment Market, By GI Tract Division:

o   Upper GI Tract

o   Lower GI Tract

• Gastrointestinal Bleeding Treatment Market, By End Users:

o   Hospital/Clinics

o   Ambulatory Surgical Centres

o   Others

• Gastrointestinal Bleeding Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gastrointestinal Bleeding Treatment Market.

Available Customizations:

Global Gastrointestinal Bleeding Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Gastrointestinal Bleeding Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]